Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763121 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
A Phase 3 study, sponsored by Areteia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,061
- Enrollment target
NCT05763121: Clinical Trial Phase 3 study, sponsored by Areteia Therapeutics.
NCT05763121 is a Phase 3 study that was terminated before completion, run by Areteia Therapeutics. The registered enrollment target is 1,061 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05763121, a Phase 3 study, was terminated before completion, sponsored by Areteia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,061 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Primary Outcome
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids; or death due to asthma.
Interventions
- DRUG Placebo
- DRUG Dexpramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,061 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Why NCT05763121 stopped before completion
NCT05763121 is an interventional study that assigns participants to a tested intervention. Its 1,061 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05763121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05763121 about?
NCT05763121 is a clinical study titled "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.". This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
What is the current status of trial NCT05763121?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,061 participants. The study started on 2023-01-30. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT05763121?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT05763121?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05763121's enrollment target sits among peer trials
1,061 275th of 2000 higher than 1,726 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI